{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T21:43:47Z","timestamp":1773006227106,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clml.2025.04.012","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T13:09:18Z","timestamp":1744895358000},"page":"e580-e590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unusually Indolent CML: Absence of Complete Cytogenetic Response after 10 Years of Tyrosine Kinase Inhibitor Therapy"],"prefix":"10.1016","volume":"25","author":[{"given":"Qiudan","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadi G.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias J.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-5959","authenticated-orcid":false,"given":"Hong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aileen Y.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-8006","authenticated-orcid":false,"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7110-3814","authenticated-orcid":false,"given":"Shimin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.clml.2025.04.012_bib0001","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2025.04.012_bib0002","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.clml.2025.04.012_bib0003","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of Imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2025.04.012_bib0004","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clml.2025.04.012_bib0005","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Brummendorf","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2025.04.012_bib0006","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus Imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clml.2025.04.012_bib0007","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib versus Imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.04.012_bib0008","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.clml.2025.04.012_bib0009","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2025.04.012_bib0010","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: eNESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.clml.2025.04.012_bib0011","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2025.04.012_bib0012","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/leu.2016.246","article-title":"Treatment and outcome of 2904 CML patients from the EUTOS population-based registry","volume":"31","author":"Hoffmann","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2025.04.012_bib0013","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0950-3536(87)80032-X","article-title":"Prognosis in chronic myeloid leukaemia: biology of the disease vs. treatment","volume":"1","author":"Sokal","year":"1987","journal-title":"Baillieres Clin Haematol"},{"issue":"4","key":"10.1016\/j.clml.2025.04.012_bib0014","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in ``good-risk'' chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.04.012_bib0015","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1038\/s41375-023-02028-2","article-title":"Survival with chronic myeloid leukaemia after failing milestones","volume":"37","author":"Lauseker","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2025.04.012_bib0016","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ajh.26836","article-title":"Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor","volume":"98","author":"Bidikian","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.04.012_bib0017","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clml.2021.07.001","article-title":"Late responses in patients with chronic myeloid leukemia initially refractory to tyrosine kinase inhibitors","volume":"22","author":"Shaya","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.04.012_bib0018","first-page":"1","article-title":"Unusually indolent CML: a stable non-responder without complete cytogenetic remission for 30 years including 17 years on tyrosine kinase inhibitor therapy","author":"Shen","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.clml.2025.04.012_bib0019","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.04.012_bib0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/leu.2016.231","article-title":"Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2025.04.012_bib0021","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3324\/haematol.2013.093765","article-title":"Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring","volume":"99","author":"Luthra","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.04.012_bib0022","series-title":"An International System for Human Cytogenomic Nomenclature","author":"McGowan-Jordan","year":"2020"},{"issue":"1","key":"10.1016\/j.clml.2025.04.012_bib0023","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.04.012_bib0024","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023 - common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J"},{"issue":"21","key":"10.1016\/j.clml.2025.04.012_bib0025","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1158\/1078-0432.CCR-18-0167","article-title":"Single-molecule sequencing reveals patterns of preexisting drug resistance that suggest treatment strategies in Philadelphia-positive leukemias","volume":"24","author":"Schmitt","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.clml.2025.04.012_bib0026","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/leu.2015.168","article-title":"BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase","volume":"29","author":"Hughes","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2025.04.012_bib0027","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.04.012_bib0028","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.clml.2025.04.012_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101194","article-title":"CML - not only BCR-ABL1 matters","volume":"33","author":"Rinke","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"9","key":"10.1016\/j.clml.2025.04.012_bib0030","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.04.012_bib0031","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/s41467-021-23097-w","article-title":"Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia","volume":"12","author":"Ochi","year":"2021","journal-title":"Nat Commun"},{"issue":"24","key":"10.1016\/j.clml.2025.04.012_bib0032","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.3390\/ijms20246141","article-title":"Mechanisms of disease progression and resistance to Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update","volume":"20","author":"Bavaro","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"26","key":"10.1016\/j.clml.2025.04.012_bib0033","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/bloodadvances.2017011858","article-title":"Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy","volume":"1","author":"Gong","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.04.012_bib0034","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/asheducation-2010.1.122","article-title":"Chronic myeloid leukemia 2010: where are we now and where can we go?","volume":"2010","author":"Radich","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"22","key":"10.1016\/j.clml.2025.04.012_bib0035","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T21:25:50Z","timestamp":1754429150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2152265025001430"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unusually Indolent CML: Absence of Complete Cytogenetic Response after 10 Years of Tyrosine Kinase Inhibitor Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}